Seeking Alpha

Biogen (BIIB +1.8%) moves up after its Q4 easily beat EPS estimates earlier this morning....

Biogen (BIIB +1.8%) moves up after its Q4 easily beat EPS estimates earlier this morning. Earnings rose 25% Y/Y on faster than expected revenue growth, helped by a jump in sales of Tysabri and Avonex. The company guides lower for FY12 however, saying revenue growth is showing signs of slowing. It now anticipates low-to mid-single-digit revenue growth in 2012.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs